Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 23, 2007 Brian Orelli	Schering Ploughed Down Investors punish the pharmaceutical company when it misses Wall Street expectations following 11 consecutive quarters of double-digit sales growth.
The Motley Fool July 24, 2007 Brian Orelli	No Pharma Love for Schering A doubling of earnings, but no jump in stock price? Schering investors, take note.
The Motley Fool July 21, 2005 Stephen D. Simpson	Schering Plows Ahead Strong sales are driving this turnaround. As long as the pharma continues to make progress with its legal and regulatory issues and simultaneously continue to deliver solid financial results, the valuation and stock price will likely work themselves out favorably over time.
The Motley Fool January 25, 2005 Stephen D. Simpson	Schering-Plough Turning a Corner The troubled pharmaceutical company begins to show signs of life. Investors looking for a more stable play would do well to look at other shares instead.
The Motley Fool March 2, 2010 Brian Orelli	Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off.
The Motley Fool October 24, 2005 Stephen D. Simpson	Vytorin Lifts Schering-Plough While the pharma is now officially in a turnaround phase, the news may already be baked into the stock.
The Motley Fool October 23, 2006 Brian Lawler	The New Schering-Plough Possibly the cheapest large-cap pharmaceutical company compared with its growth potential, the new Schering-Plough is no dirt. Investors craving only one domestic large-cap pharma stock might be happiest with the new Schering.
The Motley Fool August 28, 2008 Brian Orelli	Schering and Pfizer Aren't Horsing Around Schering sells some animal health products to Pfizer to keep the EU happy.
The Motley Fool June 11, 2007 Brian Lawler	Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul.
The Motley Fool June 11, 2007 Brian Lawler	Overseas Action for SGP Schering gets an expanded label and begins marketing another drug overseas. Investors often overlook the importance that markets outside the U.S. offer for pharmaceutical products.
The Motley Fool November 25, 2008 Brian Orelli	Schering's Peacock Imitation The company lays out its pipeline for investors to see; there are some potential blockbusters waiting there.
The Motley Fool April 21, 2005 Stephen D. Simpson	Schering-Plough Back in Black The turnaround seems to be working, as the company puts together consecutive quarters of good growth. But investors must realize that the company has a rather sparse late-stage pipeline relative to other large pharmaceutical peers.
The Motley Fool September 10, 2008 Brian Orelli	Are Drug Companies Being Shortsighted With R&D? Cutting research and development spending could be like playing with fire for pharmaceutical companies.
The Motley Fool April 20, 2006 Stephen D. Simpson	Could Schering-Plough Do More With More? An acquisition or two might make better use of the company's overhead. There could be some upside here for investors as the recovery story continues to play out.
The Motley Fool May 13, 2008 Brian Orelli	Is Merck Keeping Its Enemies Close? The drugmaker strikes a deal with an Indian generic company.
The Motley Fool September 22, 2008 Brian Orelli	Let's Bail Out Pharma Next Schering-Plough is cutting jobs. Maybe the government should help out?
The Motley Fool August 7, 2007 Brian Orelli	Financing Your Acquisition Schering-Plough is one step closer to financing its $14 billion acquisition of the Organon BioSciences unit of Akzo Nobel, by making an official stock offering.
The Motley Fool January 30, 2006 Stephen D. Simpson	Speed the Plough Schering-Plough is still in a precarious position, but it's likely to have above-average growth. It is also one of the few pharmaceuticals whose risk level is actually decreasing. This could be a stock worth owning for some time.
The Motley Fool April 24, 2008 Brian Orelli	Is Schering-Plough the Comeback Kid? Schering posts an OK quarter despite the slowdown in sales of its cholesterol drugs.
The Motley Fool February 14, 2008 Brian Orelli	A Lovey-Dovey Duo Drug companies Schering-Plough and Merck hook up to market a 'hot, hot, hot!' product.
The Motley Fool April 4, 2008 Brian Orelli	Why Is Schering Cutting Now? The latest pharmaceutical company to jump on the cost-cutting bandwagon is Schering-Plough.
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool October 21, 2008 Brian Orelli	Schering Buys Great Growth Acquiring Organon Biosciences saves the company from a rough quarter.
The Motley Fool July 21, 2009 Brian Orelli	Merck and Schering: A Less Ugly Bride and Groom Merck and Schering-Plough are up today on "better than expected" earnings, but the bride and groom don't look all that great heading into the wedding.
The Motley Fool December 10, 2008 Brian Orelli	Merck: Same Plan, With a Twist With increasing generic competition and languishing sales of cholesterol-lowering drugs Vytorin and Zetia, Merck is doing its best to replace sales by pushing new drugs through its pipeline.
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.
The Motley Fool August 12, 2011 David Williamson	What Happened to U.S. Pharma? How did the domestic pharmaceutical industry fare in the most recent quarter?
The Motley Fool February 4, 2009 Brian Orelli	The Tale of 2 Drugmakers Merck and Schering-Plough typically release earnings on the same day because they share sales of cholesterol drugs Vytorin and Zetia, but the drugmakers are far from the same.
The Motley Fool March 31, 2008 Brian Lawler	A Little Funding for Pharmasset Development-stage drugmaker Pharmasset may be on to something with its hepatitis C compounds.
The Motley Fool September 1, 2009 Brian Orelli	Merck to Bride: Leave the Jewelry at Home The new Merck will look a lot like the old Merck at the top, even though about 40% of Schering's senior leaders will be headed to the new company.
The Motley Fool July 27, 2007 Brian Lawler	Millennium Waits for the Future Millennium Pharmaceutical has eleven new drugs in the pipeline for the future, but for today all they have is lower revenue and higher expenditure guidance.
The Motley Fool July 30, 2010 Brian Orelli	It's Hard to Get Excited About 92% Revenue Growth Especially when revenue dropped on a comparable basis.
The Motley Fool April 30, 2011 Brian Orelli	No Long-Term Guidance? No Problem! Looking good, Merck.
The Motley Fool October 27, 2005 Stephen D. Simpson	A Balanced Attack for Glaxo A broad suite of drugs, a huge sales force, and a solid pipeline make GlaxoSmithKline an appealing pharmaceutical company. The problem for investors is that it's all valued into the stock.
The Motley Fool July 14, 2005 Stephen D. Simpson	These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business.
The Motley Fool April 20, 2007 Ryan Fuhrmann	Discerning Pfizer's Pfuture The company is undergoing a transformation, but that doesn't mean it isn't worth a look from investors.
The Motley Fool April 21, 2009 Brian Orelli	Schering and Merck: A Match Made in Purgatory Until Merck can show that it's capable of growing sales again, investors should be leery of stepping in, even with the dividend yield pushing 6%.
The Motley Fool May 23, 2008 Brian Lawler	Vertex's Lead Cut Down Schering-Plough is moving forward with its antiviral hepatitis C drug even faster than expected, much to Vertex's dismay.
The Motley Fool August 8, 2007 Brian Lawler	Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline.
The Motley Fool May 12, 2010 Brian Orelli	Is Merck a Buy? Short term it's hard to say, but for the long term, its pipeline looks strong.
The Motley Fool February 3, 2011 Brian Orelli	Get Ready for Merck's Bumpy Ride Long-term earnings guidance gets thrown out the window.
The Motley Fool March 31, 2008 Brian Orelli	No Blood-Pumping Love for Merck and Schering From the reports coming out of the American College of Cardiology meeting, it looks like the drugmakers Merck and Schering-Plough took a beating.
The Motley Fool May 21, 2009 Brian Orelli	Not So Fast, Schering ... er, Merck ... er, Whoever You Are Merck got cute with its acquisition of Schering-Plough by setting up the merger so that Schering is technically merging with Merck and then changing its name to Merck. That seemingly schizophrenic move had a purpose.
The Motley Fool August 30, 2010 Brian Orelli	Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help.
The Motley Fool November 4, 2009 Brian Orelli	An Ode to Schering-Plough Mergers and acquisitions in the pharmaceutical industry are cataloged in a poem.
The Motley Fool August 4, 2008 Brian Lawler	Vertex on the Verge of Victory Like the majority of biotech drugmakers, Vertex's financials proved less crucial in the second quarter than the clinical trial results from the drugmaker's pipeline.
The Motley Fool February 13, 2008 Brian Orelli	Schering-Plough Has No Love for the Media Apart from the press bashing regarding the company's cholesterol-lowering drug Enhance, Schering reported a pretty nice quarter.
The Motley Fool May 5, 2010 Brian Orelli	Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is.
The Motley Fool January 25, 2005 Stephen D. Simpson	Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today.
The Motley Fool October 23, 2009 Brian Orelli	Merck-Schering Doesn't Look So Good Revenue is stagnant; let's hope that pipeline pans out.